(Q34481976)

2 August 2017

1 reference

title

Advances in the non-surgical treatment of melanoma (English)

1 reference

2 August 2017

Peter Hersey

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

11

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

75-85

1 reference

Rearrangement of immunoglobulin genes in shark germ cells

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Mitochondria-dependent and -independent regulation of Granzyme B-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Apoptosis control by death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

The molecular control of DNA damage-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

From bench to clinic with apoptosis-based therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Nuclear and mitochondrial apoptotic pathways of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Effects of betulinic acid alone and in combination with irradiation in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.75

21 January 2018

Identifiers

DOI

10.1517/13543784.11.1.75

1 reference

2 August 2017

1 reference